# Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

> **NCT04128137** · PHASE4 · UNKNOWN · sponsor: **H.A.C. PHARMA** · enrollment: 90 (estimated)

## Conditions studied

- Neurogenic Orthostatic Hypotension

## Interventions

- **DRUG:** Fludrocortisone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04128137
- **Lead sponsor:** H.A.C. PHARMA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-09
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128137, "Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04128137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*